WT1 and cancer: This study showed that spontaneous IL-10 secretion and HTL epitope WT1-332-specific IL-10 secretion from PBMCs before vaccination were associated with a poor clinical prognosis in patients with recurrent malignant glioma treated with the WT1 Trio cancer vaccine.